ClinicalTrials.gg
Not yet recruitingNCT05909826KMM-KCdUpdated Jun 18, 2023

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

A Phase 2 interventional study of Carfilzomib and Cyclophosphamide in Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Dong-A University Hospital. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Dong-A University Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Planned enrollment
64th of 113
49 · median 54
Started
2023
with 5 others
Phase 2
50 of 113
6 open now
Primary completion
2027-06
later than 22 of 38 live
Registered
104th of 113
by date

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 64th largest by planned enrollment, is one of 6 that started in 2023, is one of 50 in phase 2, reaches primary completion later than 22 of the 38 other live ones, and was the 104th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.

Read the detailed description

The survival of multiple myeloma (MM) patients has been improved significantly owing to the adoption of immunomodulatory agents (IMiD) and proteasome inhibitors (PI). However, most of the MM patients finally experience relapse of refractoriness of the disease, of which patients who relapse after bortezomib and lenalidomide have very poor prognosis. Carfilzomib is an irreversible second generation PI which is approved by Korean FDA for RRMM in combination with dexamethasone and/or lenalidomide based on the landmark studies ASPIRE and ENDEAVOR studies. The addition of intravenous cyclophosphamide to carfilzomib has recently showed a promising result for RRMM patients after bortezomib and lenalidomide. In this study, cyclophosphamide 50mg orally will be added to carfilzomib once weekly schedule for 21 days daily every 4 weeks. The rationale for oral metronomic cyclophosphamide is based on previous experimental studies which has shown that it removes CD4+CD25+regulatory T cells preserving T and NK/T cell funtions.

03

Conditions studied

  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 19 years or older
  2. performance status 0 to 2
  3. Diagnosed with multiple myeloma by IMWG criteria
  4. Subjects previously treated with 1 or more
  5. Subjects previously treated with lenalidomide-based combination or sigle drug therapy
  6. Subjects with multiple myeloma
  7. Subjects with at the time of treatment initiation

    • serum M protein >=0.5 g/dL, or
    • 24h urine M protein >= 200mg/24h
    • serum free light chain difference >=10mg/dL and abnormal FLC ratio
  8. Adequate organ function

    • >= 1.0 x 109/L
    • platelelt count >= 50 x 109/L (plasmacytoma in the bone: >=30 x 109/L)
    • >=8g/dL
    • serum creatinine \< 3.0mg/dL or CCR >=15mL/min
    • serum and ALT \<=3 x
    • serum total \<= 3 x ULN
  9. Subjects able to swallow oral drugs
  10. Subjects who had experienced toxicities to previous therapies: resolved from previous toxicities or stabilized of the toxicity to grade 1
  11. Subjects who had received allogenetic stem cell transplantation: no acitve
  12. Subjects without bleeding
  13. Subjects who have to the study
  14. Females of (FCBP) must be negative to pregnancy testing and give consent to practice before and during the treatment

Exclusion criteria

Exclusion Criteria:

  1. Subjects who were previously exposed to carfilzomib
  1. Subjects who were previously exposed to cyclophosphamide 3. Subjects diagnosed with POEMS SD, Waldenstrom macroglobulinemia, Plasma cell leukemia 4. Subjects with concurrent heart conditions
  • Myocardial infarction within 6 months prior to treatment, class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease,
  • Uncontrolled arrythmias (CVDAE version4 grade 2 or more) or symptomatic abnormalities
  • 12-lead EKG : baseline ATcF > 470msec
  • 2D Echocardiography or : systolic EF \< 40% with symptoms
  • Uncontrolled hypertension ( with medication: systolic BP >= 160 mmHg or diastolic BP >= 100 mmHg) 5. Chronc obstructive pulmonary disease ( \< 60%), history of asthma within 2 years 6. Surgery under general anesthesia withing 2 weeks 7. Subjects diagnosed with within 5 years (except for cured skin cancer, cervical cancer, intraepithelial gastrointestinal tract cancer after curative procedures or surgery for more than 3 years) 8. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give 9. Pregnant or breatfeeding subjecs
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    Weekly carfilzomib-oral cyclophosphamide-dexamethasone

    Weekly carfilzomib-oral cyclophosphamide-dexamethasone

    Drug: Carfilzomib · Drug: Cyclophosphamide · Drug: Dexamethasone

Interventions

  • 70 mg/m2 IV days 1, 8 and 15, every 4 weeks

    Also known as: Kyprolis

  • 50 mg PO days 1 to 21, every 4 weeks

    Also known as: Alkyloxan

  • 40mg PO or IV days 1, 8, 15, and 22, every 4 weeks

06

What researchers measure

Primary outcomes

  1. Very good partial response

    Reduction of serum M-protein \> 90%

    Time frame: from the first date of KCd to the day 30 after KCd stop date

Secondary outcomes

  1. Overall response

    sCR+CR+VGPR+PR

    Time frame: from the first date of KCd to the day 30 after KCd stop date

  2. Progression-free survival

    the time from the first date of KCd to the date of disease progression or death or censored date

    Time frame: from the first date of KCd until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  3. Overall survival

    the time from the first date of KCd to the date of death or censored date

    Time frame: from the first date of KCd until the date of death from any cause, assessed up to 48 months

  4. Duration of response

    the time from the first date of PR to the date of disease progression or death or censord date

    Time frame: from the first date of PR to the date of disease progression or death or censord date, which ever came first, assessed up to 48 months

  5. Time to response

    the time from the first date of KCd to the first date of partial response

    Time frame: from the first date of KCd to the date of first date of equal or more than partial response, which ever came first, assessed up to 48 months

  6. Safety profile

    Adverse events after KCd

    Time frame: from the first date of KCd to day 30 after KCd stop date

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Jun 2027, 47 months later.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 47 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Jun 18, 2023
StartEst.
Jul 1, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05909826
Lead sponsor
Dong-A University Hospital
Responsible party
Sung-Hyun Kim (Professor, Dong-A University Hospital) — Principal investigator
First posted
Jun 18, 2023
Start date
Jul 1, 2023 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 18, 2023

Study contacts

Ji Hyun Lee, MD, Ph.D
Contact
hidrleejh@dau.ac.kr
82-51-240-2915
Sung-Hyun Kim, MD, Ph.D
principal investigator · Dong-A University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Cyclophosphamide · Dexamethasone

Start the discussion